<?xml version='1.0' encoding='utf-8'?>
<document id="18420781"><sentence text="An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction."><entity charOffset="47-58" id="DDI-PubMed.18420781.s1.e0" text="desipramine" /><entity charOffset="59-68" id="DDI-PubMed.18420781.s1.e1" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.18420781.s1.e0" e2="DDI-PubMed.18420781.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18420781.s1.e0" e2="DDI-PubMed.18420781.s1.e1" /></sentence><sentence text="There are documented clinical drug-drug interactions between bupropion and the CYP2D6-metabolized drug desipramine resulting in marked (5-fold) increases in desipramine exposure"><entity charOffset="61-70" id="DDI-PubMed.18420781.s2.e0" text="bupropion" /><entity charOffset="103-114" id="DDI-PubMed.18420781.s2.e1" text="desipramine" /><entity charOffset="157-168" id="DDI-PubMed.18420781.s2.e2" text="desipramine" /><pair ddi="false" e1="DDI-PubMed.18420781.s2.e0" e2="DDI-PubMed.18420781.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18420781.s2.e0" e2="DDI-PubMed.18420781.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18420781.s2.e0" e2="DDI-PubMed.18420781.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18420781.s2.e1" e2="DDI-PubMed.18420781.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18420781.s2.e1" e2="DDI-PubMed.18420781.s2.e2" /></sentence><sentence text=" This finding was unexpected as CYP2D6 does not play a significant role in bupropion clearance, and bupropion and its major active metabolite, hydroxybupropion, are not strong CYP2D6 inhibitors in vitro"><entity charOffset="75-84" id="DDI-PubMed.18420781.s3.e0" text="bupropion" /><entity charOffset="100-109" id="DDI-PubMed.18420781.s3.e1" text="bupropion" /><entity charOffset="143-159" id="DDI-PubMed.18420781.s3.e2" text="hydroxybupropion" /><pair ddi="false" e1="DDI-PubMed.18420781.s3.e0" e2="DDI-PubMed.18420781.s3.e0" /><pair ddi="false" e1="DDI-PubMed.18420781.s3.e0" e2="DDI-PubMed.18420781.s3.e1" /><pair ddi="false" e1="DDI-PubMed.18420781.s3.e0" e2="DDI-PubMed.18420781.s3.e2" /><pair ddi="false" e1="DDI-PubMed.18420781.s3.e1" e2="DDI-PubMed.18420781.s3.e1" /><pair ddi="false" e1="DDI-PubMed.18420781.s3.e1" e2="DDI-PubMed.18420781.s3.e2" /></sentence><sentence text=" The aims of this study were to investigate whether bupropion's reductive metabolites, threohydrobupropion and erythrohydrobupropion, contribute to the drug interaction with desipramine"><entity charOffset="174-185" id="DDI-PubMed.18420781.s4.e0" text="desipramine" /></sentence><sentence text=" In human liver microsomes using the CYP2D6 probe substrate bufuralol, erythrohydrobupropion and threohydrobupropion were more potent inhibitors of CYP2D6 activity (K(i) = 1"><entity charOffset="60-69" id="DDI-PubMed.18420781.s5.e0" text="bufuralol" /><entity charOffset="71-92" id="DDI-PubMed.18420781.s5.e1" text="erythrohydrobupropion" /><entity charOffset="97-116" id="DDI-PubMed.18420781.s5.e2" text="threohydrobupropion" /><pair ddi="false" e1="DDI-PubMed.18420781.s5.e0" e2="DDI-PubMed.18420781.s5.e0" /><pair ddi="false" e1="DDI-PubMed.18420781.s5.e0" e2="DDI-PubMed.18420781.s5.e1" /><pair ddi="false" e1="DDI-PubMed.18420781.s5.e0" e2="DDI-PubMed.18420781.s5.e2" /><pair ddi="false" e1="DDI-PubMed.18420781.s5.e1" e2="DDI-PubMed.18420781.s5.e1" /><pair ddi="false" e1="DDI-PubMed.18420781.s5.e1" e2="DDI-PubMed.18420781.s5.e2" /></sentence><sentence text="7 and 5" /><sentence text="4 microM, respectively) than hydroxybupropion (K(i) = 13 microM) or bupropion (K(i) = 21 microM)"><entity charOffset="29-45" id="DDI-PubMed.18420781.s7.e0" text="hydroxybupropion" /><entity charOffset="68-77" id="DDI-PubMed.18420781.s7.e1" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.18420781.s7.e0" e2="DDI-PubMed.18420781.s7.e0" /><pair ddi="false" e1="DDI-PubMed.18420781.s7.e0" e2="DDI-PubMed.18420781.s7.e1" /></sentence><sentence text=" Furthermore, neither bupropion nor its metabolites were metabolism-dependent CYP2D6 inhibitors"><entity charOffset="22-31" id="DDI-PubMed.18420781.s8.e0" text="bupropion" /></sentence><sentence text=" Using the in vitro kinetic constants and estimated liver concentrations of bupropion and its metabolites, modeling was able to predict within 2-fold the increase in desipramine exposure observed when coadministered with bupropion"><entity charOffset="76-85" id="DDI-PubMed.18420781.s9.e0" text="bupropion" /><entity charOffset="166-177" id="DDI-PubMed.18420781.s9.e1" text="desipramine" /><entity charOffset="221-230" id="DDI-PubMed.18420781.s9.e2" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.18420781.s9.e0" e2="DDI-PubMed.18420781.s9.e0" /><pair ddi="false" e1="DDI-PubMed.18420781.s9.e0" e2="DDI-PubMed.18420781.s9.e1" /><pair ddi="false" e1="DDI-PubMed.18420781.s9.e0" e2="DDI-PubMed.18420781.s9.e2" /><pair ddi="false" e1="DDI-PubMed.18420781.s9.e1" e2="DDI-PubMed.18420781.s9.e1" /><pair ddi="false" e1="DDI-PubMed.18420781.s9.e1" e2="DDI-PubMed.18420781.s9.e2" /></sentence><sentence text=" This work indicates that the reductive metabolites of bupropion are potent competitive CYP2D6 inhibitors in vivo and provides a mechanistic explanation for the clinical drug-drug interaction between bupropion and desipramine"><entity charOffset="55-64" id="DDI-PubMed.18420781.s10.e0" text="bupropion" /><entity charOffset="200-209" id="DDI-PubMed.18420781.s10.e1" text="bupropion" /><entity charOffset="214-225" id="DDI-PubMed.18420781.s10.e2" text="desipramine" /><pair ddi="false" e1="DDI-PubMed.18420781.s10.e0" e2="DDI-PubMed.18420781.s10.e0" /><pair ddi="false" e1="DDI-PubMed.18420781.s10.e0" e2="DDI-PubMed.18420781.s10.e1" /><pair ddi="false" e1="DDI-PubMed.18420781.s10.e0" e2="DDI-PubMed.18420781.s10.e2" /><pair ddi="false" e1="DDI-PubMed.18420781.s10.e1" e2="DDI-PubMed.18420781.s10.e1" /><pair ddi="false" e1="DDI-PubMed.18420781.s10.e1" e2="DDI-PubMed.18420781.s10.e2" /></sentence><sentence text="" /></document>